As another quarter rounds out, a new batch of drugs have been approved by the US Food and Drug Administration for conditions often seen in primary care - quite a few of them first-in-class or novel in another way. For example, the first and only pneumococcal vaccine formulated specifically to protect adults 50 years and older; the first mRNA vaccine against RSV for adults aged 60 years and older; and the first inhaled product with a novel mechanism of action approved for maintenance chronic obstructive pulmonary disease (COPD) treatment in over 20 years. In the slides below, we recap these drugs and 5 more.
Missed last quarter's drug roundup? Check out 7 Drugs Approved for Primary Care: Q1 2024
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.